Akari Therapeutics targets mid-2027 start for AKTX-101 Phase 1 trial
AKTX•AKTX•AKTX•AKTX•Akari Therapeutics is advancing AKTX-101 through preclinical safety studies and manufacturing, targeting a Phase 1 start in mid-2027. The PH1 payload is designed to disrupt RNA splicing in cancer cells, and the company is exploring potential partnerships and licensing.
Akari Therapeutics is advancing AKTX-101 through preclinical safety studies and manufacturing, targeting Phase 1 clinical development in mid-2027.
The PH1 payload is designed to disrupt RNA splicing in cancer cells, offering a different approach from commonly used ADC payloads. Clinical data presented at medical conferences showed no benefit from sequential ADC treatments using the same payload class following relapse. Potential strategic partnerships and payload licensing remain under discussion as Akari explores a broader ADC pipeline.
